Basaglar insulin's price can vary significantly depending on factors like insurance coverage, pharmacy, and location. However, it is generally positioned as a more affordable alternative to Lantus, its reference biologic.
How much does Basaglar cost without insurance?
Without insurance, the out-of-pocket cost for a box of Basaglar KwikPens (which typically contains five 3-milliliter pens) can range from approximately $100 to $150 or more [1]. Prices can fluctuate based on the specific pharmacy and region.
Does insurance cover Basaglar?
Many insurance plans cover Basaglar, often at a lower tier than Lantus, which can result in a reduced copay for patients. Coverage details and copay amounts are plan-specific and best confirmed directly with the insurance provider.
Are there discount programs for Basaglar?
Eli Lilly and Company, the manufacturer of Basaglar, offers savings cards and discount programs that can help eligible commercially insured patients reduce their out-of-pocket costs [2]. These programs typically have terms and conditions, such as maximum savings limits and eligibility criteria.
How does Basaglar pricing compare to Lantus?
Basaglar was developed as a follow-on product to Lantus (insulin glargine injection) and is bioequivalent, meaning it works the same way in the body. Its introduction into the market was intended to provide a more cost-effective insulin glargine option. Consequently, Basaglar is generally priced lower than Lantus [3].
What is Basaglar?
Basaglar is a brand name for insulin glargine, a long-acting insulin used to treat type 1 and type 2 diabetes. It is administered once daily to help control blood sugar levels [4]. As a biosimilar, it is highly similar to its reference product, Lantus, with no clinically meaningful differences in safety, purity, and potency [3].
When did Basaglar become available?
Basaglar received FDA approval in December 2015 and became available in the U.S. in December 2016 [5].
Who makes Basaglar?
Basaglar is manufactured by Eli Lilly and Company [2].
What are the patent considerations for Basaglar?
The development and availability of biosimilars like Basaglar are influenced by patent expirations and litigation surrounding the reference biologic, Lantus. Information on specific patent landscapes and any legal challenges can be found on resources like DrugPatentWatch.com [6].
What are patient assistance programs for insulin?
Beyond manufacturer-specific programs, various patient assistance foundations and non-profit organizations offer help with prescription medication costs for those who meet specific financial criteria. Eligibility and available assistance vary by program.